Cover Image
市場調查報告書

Aeglea BioTherapeutics Holdings, LLC- 產品平台檢討

Aeglea BioTherapeutics Holdings, LLC - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 329069
出版日期 內容資訊 英文 20 Pages
訂單完成後即時交付
價格
Back to Top
Aeglea BioTherapeutics Holdings, LLC- 產品平台檢討 Aeglea BioTherapeutics Holdings, LLC - Product Pipeline Review - 2015
出版日期: 2015年03月26日 內容資訊: 英文 20 Pages
簡介

Aeglea BioTherapeutics Holdings, LLC是總公司設置於美國的生物科技企業,正在開發治療癌症的治療用酵素·搭配診斷。目前開發中的平台藥物有AERase, AECase and AEMase。

本報告提供Aeglea BioTherapeutics Holdings, LLC的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Aeglea BioTherapeutics Holdings, LLC的基本資料

  • Aeglea BioTherapeutics Holdings, LLC概要
  • 主要資訊
  • 企業資料

Aeglea BioTherapeutics Holdings, LLC:R&D概要

  • 主要的治療範圍

Aeglea BioTherapeutics Holdings, LLC:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Aeglea BioTherapeutics Holdings, LLC:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Aeglea BioTherapeutics Holdings, LLC:藥物簡介

  • AEB-1102
  • AEB-3103
  • AEB-2109 13
  • AEB-4104

Aeglea BioTherapeutics Holdings, LLC:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

Aeglea BioTherapeutics Holdings, LLC:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

目錄
Product Code: GMDHC06857CDB

Global Markets Direct's, 'Aeglea BioTherapeutics Holdings, LLC - Product Pipeline Review - 2015', provides an overview of the Aeglea BioTherapeutics Holdings, LLC 's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Aeglea BioTherapeutics Holdings, LLC 's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Aeglea BioTherapeutics Holdings, LLC including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Aeglea BioTherapeutics Holdings, LLC 's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Aeglea BioTherapeutics Holdings, LLC 's pipeline products

Reasons to buy

  • Evaluate Aeglea BioTherapeutics Holdings, LLC 's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Aeglea BioTherapeutics Holdings, LLC in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Aeglea BioTherapeutics Holdings, LLC 's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Aeglea BioTherapeutics Holdings, LLC and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Aeglea BioTherapeutics Holdings, LLC
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Aeglea BioTherapeutics Holdings, LLC and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Aeglea BioTherapeutics Holdings, LLC Snapshot
    • Aeglea BioTherapeutics Holdings, LLC Overview
    • Key Information
    • Key Facts 4
  • Aeglea BioTherapeutics Holdings, LLC - Research and Development Overview
    • Key Therapeutic Areas
  • Aeglea BioTherapeutics Holdings, LLC - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Aeglea BioTherapeutics Holdings, LLC - Pipeline Products Glance
    • Aeglea BioTherapeutics Holdings, LLC - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Aeglea BioTherapeutics Holdings, LLC - Drug Profiles
    • AEB-1102
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AEB-3103
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AEB-2109 13
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AEB-4104
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Aeglea BioTherapeutics Holdings, LLC - Pipeline Analysis
    • Aeglea BioTherapeutics Holdings, LLC - Pipeline Products by Target
    • Aeglea BioTherapeutics Holdings, LLC - Pipeline Products by Molecule Type
    • Aeglea BioTherapeutics Holdings, LLC - Pipeline Products by Mechanism of Action
  • Aeglea BioTherapeutics Holdings, LLC - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Aeglea BioTherapeutics Holdings, LLC , Key Information
  • Aeglea BioTherapeutics Holdings, LLC , Key Facts
  • Aeglea BioTherapeutics Holdings, LLC - Pipeline by Indication, 2015
  • Aeglea BioTherapeutics Holdings, LLC - Pipeline by Stage of Development, 2015
  • Aeglea BioTherapeutics Holdings, LLC - Monotherapy Products in Pipeline, 2015
  • Aeglea BioTherapeutics Holdings, LLC - Preclinical, 2015
  • Aeglea BioTherapeutics Holdings, LLC - Discovery, 2015
  • Aeglea BioTherapeutics Holdings, LLC - Pipeline by Target, 2015
  • Aeglea BioTherapeutics Holdings, LLC - Pipeline by Molecule Type, 2015
  • Aeglea BioTherapeutics Holdings, LLC - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • Aeglea BioTherapeutics Holdings, LLC - Pipeline by Top 10 Indication, 2015
  • Aeglea BioTherapeutics Holdings, LLC - Pipeline by Stage of Development, 2015
  • Aeglea BioTherapeutics Holdings, LLC - Monotherapy Products in Pipeline, 2015
  • Aeglea BioTherapeutics Holdings, LLC - Pipeline by Top 10 Target, 2015
  • Aeglea BioTherapeutics Holdings, LLC - Pipeline by Top 10 Molecule Type, 2015
  • Aeglea BioTherapeutics Holdings, LLC - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top